Nephrologists can expect some new IV iron and phosphate binder products to be launched this year
A new report by BioTrends Research Group predicts that some new products may be launched in the IV iron and hyperphosphatemia markets this year. The Exton, Pa., firm said that a new form of intravenous iron, ferumoxytol, from AMAG Pharmaceuticals could be available in the second half of this year. In a survey of 305 clinical nephrologists that BioTrends did last December, it found that 68% are not familiar with this product. BioTrends added that in the phosphate binder market, respondents feel that there is a strong need for new products, but knowledge of new binders, such as Genzyme's recently approved Renvela (sevelamer carbonate), is low. Renvela is expected to launch in the first quarter.